Little Green Pharma Ltd (ASX: LGP) signs a five-year exclusive pharmaceutical distribution agreement with Medezin Sp. z.o.o for the distribution of LGP’s cannabis medicines into Poland.
LGP will supply medicinal cannabis oils and medicinal cannabis flower product for distribution into Poland by Medezin under the Agreement, which provides Medezin with the exclusive rights to distribute LGP medicinal cannabis products, subject to meeting certain sales hurdles.
Medezin is targeting the sale of Products equivalent to:
- at least 20% of the Polish medicinal cannabis oil Market; and
- at least 10% of the Polish high-THC medicinal cannabis flower Market.
LGP Managing Director, Fleta Solomon, said the financial value of the Agreement will be contingent upon the final number of orders under the Agreement, which in turn are subject to the Minimum Order requirement.
Our distribution agreement with Medezin reflects LGP’s strategic ambition to acquire and maintain a substantial share of the Total Addressable Market in each jurisdiction we supply,” Ms Solomon said.
“We are very pleased to have partnered with Medezin, a highly experienced and large-scale pharmaceutical distributor servicing the Polish market, to help us achieve this goal.”
Pelion SA is the largest company in the Polish and Lithuanian healthcare sector, with nearly 10 billion PLN (~A$3.5 billion) in annual revenue and a 30-year operating history covering all areas of pharmaceutical distribution.
Medezin specialises in services to local and offshore pharmaceutical manufacturers and distributors, helping them with market access, importation, distribution and logistics, medical marketing or repackaging.
